Evidence map›Paper›PMID 41540298›Full record

ReviewPharmaceutical research2026

Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody-Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization.

Jialing Zhang, Weiyu Li, Meng Li, Gang Wu, Yongbo Ni, Jialiang Du, Gangling Xu, Maoqin Duan, Yalan Yang, Xiaojuan Yu and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jialing Zhang *State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Weiyu Li *State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Meng Li *State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Gang WuState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Yongbo NiState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Jialiang DuState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Gangling XuState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Maoqin DuanState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Yalan YangState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Xiaojuan YuState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Chunbo CuiState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Chunyu LiuState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China.
Chuanfei YuState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China. yucf@nifdc.org.cn.
Lan WangState Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research On Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, Zip code: 102629, P.R. China. wanglan@nifdc.org.cn.

Funding

Key Technologies Research and Development Program 2023YFC3404004
6 · The paper itself

Abstract

objectivesThe present review aims to provide comprehensive bench-to-bedside insights into ADC-related ocular toxicity for drug designers, pharmaceutical manufacturers, toxicologists, and medical staff, thereby enhancing the safety of ADC therapeutic applications.

methodsThe review comprehensively analyzes the recent progress in the pathological mechanisms of ADC-related ocular toxicity, evaluates existing non-clinical risk assessment strategies based on animal toxicological studies, and highlights future optimization directions. It also summarizes clinical adverse events to demonstrate the typical profile of ocular surface toxicity and provides clinical management strategies.

resultsADC ocular toxicity primarily affects the ocular surface via on-target (antibody-mediated) and off-target (non-specific uptake) mechanisms. Key determinants include payload type (e.g., MMAF and DM4, which exhibit higher toxicity due to intracellular retention), linker properties (cleavable linkers mitigate off-target effects), and ADCs' physicochemical characteristics. Non-clinical models effectively predict corneal injury but poorly recapitulate conjunctival responses. Clinical management relies on early ophthalmic monitoring and dose adjustment, with 42.9%-100% of adverse events being reversible.

conclusionThis review offers valuable insights into ADC ocular toxicity, emphasizing the importance of early-stage selection and optimization of ADCs and their components to reduce ocular toxicity risks. It provides a reference for mitigating ADC-related ocular toxicity risks and facilitates the future development of ADCs with improved safety and efficacy.

Indexed as

EyeEye DiseasesImmunoconjugatesAnimalsHumansImmunoconjugatesantibody–drug conjugates (ADcs)clinical and non-clinical manifestationsmanagement strategiesmolecular optimizationocular toxicity pathogenesis

Identifiers

PMID41540298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.